The Impact of Physician-Pharmacist Collaborative Drug Therapy Management in Gender-Affirming Care

Clicks: 8
ID: 328237
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #160 of 189 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 189 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: To describe the implementation and early experience of a pharmacist-led collaborative drug therapy management (CDTM) service delivering gender-affirming hormone therapy (GAHT) and integrated preventive care within an urban safety-net hospital. SUMMARY: A CDTM pilot program was implemented in November 2023 at the Pride Health Center within NYC Health + Hospitals/Bellevue. Through collaborative agreements with primary care physicians, a board-certified ambulatory care pharmacist independently initiated and titrated hormone therapy and concurrently managed HIV prevention and treatment, sexually transmitted infections, and chronic disease states. Protocols developed jointly with physicians specified medications and laboratory tests the pharmacist could order independently. Between November 2023 and February 2025, 70 patients enrolled and completed 223 visits, during which the pharmacist documented 573 interventions, including 76 GAHT initiations, 28 PrEP initiations, 20 DoxyPEP initiations, and management of 62 adverse drug reactions under protocol. Among 58 patients completing a satisfaction survey, all reported feeling respected and supported by the pharmacist, and 95% strongly agreed they were pleased with the service. CONCLUSION: A pharmacist practicing under CDTM independently initiated and managed gender-affirming hormone therapy while delivering integrated preventive care in a safety-net setting. The model was well received by patients and may be replicable at institutions with established LGBTQIA+ services and collaborative practice frameworks.
Reference Key
openalex_W7212163587 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anthony Gerber, Josh Rickard
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag278
URL
https://doi.org/10.1093/ajhp/zxag278
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.